Actinium Pharmaceuticals unveiled findings at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting regarding the efficacy of Iomab-B in treating patients with relapsed or refractory acute myeloid leukemia (r/r AML). According to the Phase 3 SIERRA trial data, Iomab-B, a targeted radiotherapy, successfully achieved its primary endpoint of durable Complete Remission with high statistical significance.
The trial, which focused on a subset of 37 patients with a TP53 mutation, revealed that those treated with Iomab-B experienced a median overall survival of 5.49 months, significantly longer than the 1.66 months observed in untreated patients. Notably, Iomab-B demonstrated the ability to deliver concentrated radiation to diseased bone marrow while minimizing exposure to healthy organs, offering a potentially superior alternative to total body irradiation.
Actinium Pharmaceuticals also presented its innovative linker technology for solid tumor indications, showcasing reduced kidney and liver uptake in preclinical models, indicating improved targeted radiotherapy delivery. The company is moving forward with Iomab-B nearing pre-BLA & MAA (EU) stages and Actimab-A on a pivotal development path with the National Cancer Institute.
As reported by Investing.com, actinium is driving advancements in Ac-225 production through its proprietary cyclotron-based manufacturing technology, with plans for substantial investments and global collaborations to meet the growing demand for Ac-225. Additionally, the company is advancing its Iomab-ACT program, aiming to improve access and outcomes for patients requiring cellular or gene therapies.